These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33565324)

  • 1.
    Srisuttayasathien M; Areepium N; Lertkhachonsuk R
    Per Med; 2021 Mar; 18(2):107-114. PubMed ID: 33565324
    [No Abstract]   [Full Text] [Related]  

  • 2. Presence of the methylenetetrahydrofolate reductase gene polymorphism MTHFR C677T in molar tissue but not maternal blood predicts failure of methotrexate treatment for low-risk gestational trophoblastic neoplasia.
    Qu J; Usui H; Kaku H; Shozu M
    Eur J Pharmacol; 2017 Jan; 794():85-91. PubMed ID: 27840191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 667C>T and 1298A>C polymorphisms of MTHFR do not predict response to methotrexate in patients with gestational trophoblastic neoplasia.
    Lasecka L; Dixon PH; Molokhia M; Sharma N; Schleh A; Wang CM; Steel JH; Seckl MJ; Savage PM; Fisher RA
    Gynecol Oncol; 2011 Dec; 123(3):605-9. PubMed ID: 21920590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uterine artery pulsatility index and serum BMP-9 predict resistance to methotrexate therapy in gestational trophoblastic neoplasia: A cohort study.
    Harvey RA; Elias KM; Lim A; Bercow A; Short D; Horowitz NS; Berkowitz RS; Agarwal R; Seckl MJ
    Curr Probl Cancer; 2021 Feb; 45(1):100622. PubMed ID: 32800689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early prediction of post-molar gestational trophoblastic neoplasia and resistance to methotrexate, based on a single serum human chorionic gonadotropin measurement.
    Hoeijmakers YM; Eysbouts YK; Massuger LFAG; Dandis R; Inthout J; van Trommel NE; Ottevanger PB; Thomas CMG; Sweep FCGJ
    Gynecol Oncol; 2021 Dec; 163(3):531-537. PubMed ID: 34602288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Oral Vitamin A in Reducing β-hCG Levels in Low-Risk Gestational Trophoblastic Neoplasia Patients.
    Hidayat YM; Darmadi A E; Rachmayati S; Kusumah WP; Djuwantono T; Pramatirta AY; Suardi D
    Asian Pac J Cancer Prev; 2020 Nov; 21(11):3325-3329. PubMed ID: 33247691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doppler-based predictive model for methotrexate resistance in low-risk gestational trophoblastic neoplasia with myometrial invasion: prospective study of 147 patients.
    Qin J; Zhang S; Poon L; Pan Z; Luo J; Yu N; Wang L; Wu X; Cheng X; Xie X; Lu Y; Lu W
    Ultrasound Obstet Gynecol; 2021 May; 57(5):829-839. PubMed ID: 32385928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience.
    Maestá I; Nitecki R; Horowitz NS; Goldstein DP; de Freitas Segalla Moreira M; Elias KM; Berkowitz RS
    Gynecol Oncol; 2018 Jan; 148(1):161-167. PubMed ID: 29092742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does methotrexate (MTX) dosing in a 8-day MTX/FA regimen for the treatment of low-risk gestational trophoblastic neoplasia affect outcomes? The MITO-9 study.
    Mangili G; Cioffi R; Danese S; Frigerio L; Ferrandina G; Cormio G; Rabaiotti E; Scarfone G; Gadducci A; Bergamini A; Pisano C; Candiani M
    Gynecol Oncol; 2018 Dec; 151(3):449-452. PubMed ID: 30266260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Combination Therapy with Actinomycin D and Methotrexate in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia.
    Kang HL; Zhao Q; Yang SL; Duan W
    Chemotherapy; 2019; 64(1):42-47. PubMed ID: 31163446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment results of the second-line chemotherapy regimen for patients with low-risk gestational trophoblastic neoplasia treated with 5-day methotrexate and 5-day etoposide.
    Kanno T; Matsui H; Akizawa Y; Usui H; Shozu M
    J Gynecol Oncol; 2018 Nov; 29(6):e89. PubMed ID: 30207097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uterine artery pulsatility index: a predictor of methotrexate resistance in gestational trophoblastic neoplasia.
    Agarwal R; Harding V; Short D; Fisher RA; Sebire NJ; Harvey R; Patel D; Savage PM; Lim AK; Seckl MJ
    Br J Cancer; 2012 Mar; 106(6):1089-94. PubMed ID: 22374461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-risk gestational trophoblastic neoplasia and methotrexate resistance: predictors of response to treatment with actinomycin D and need for combination chemotherapy.
    Growdon WB; Wolfberg AJ; Goldstein DP; Feltmate CM; Chinchilla ME; Lieberman ES; Berkowitz RS
    J Reprod Med; 2010; 55(7-8):279-84. PubMed ID: 20795339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of an online tool for early prediction of the failure-risk in gestational trophoblastic neoplasia patients treated with methotrexate.
    Dekeister K; Bolze PA; Tod M; Tod R; Massardier J; Lotz JP; Hajri T; Colomban O; Seckl MJ; Osborne R; Freyer G; Golfier F; You B
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):15-24. PubMed ID: 32500221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Curative effects and influenced factors of primary chemotherapy with single-agent methotrexate on low-risk gestational trophoblastic neoplasia].
    Wu XD; Chen LL; Shen T; Chen SS; Chen QQ; Qin JL; Fu YF; Lü WG
    Zhonghua Yi Xue Za Zhi; 2017 Jun; 97(23):1769-1772. PubMed ID: 28647996
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy.
    Chapman-Davis E; Hoekstra AV; Rademaker AW; Schink JC; Lurain JR
    Gynecol Oncol; 2012 Jun; 125(3):572-5. PubMed ID: 22449733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia?
    Mora PAR; Sun SY; Velarde GC; Filho JR; Uberti EH; Dos Santos Esteves APV; Elias KM; Horowitz NS; Braga A; Berkowitz RS
    Gynecol Oncol; 2019 May; 153(2):277-285. PubMed ID: 30857648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.
    Rakhmanina NY; Neely MN; Van Schaik RH; Gordish-Dressman HA; Williams KD; Soldin SJ; van den Anker JN
    Ther Drug Monit; 2011 Aug; 33(4):417-24. PubMed ID: 21743379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of an initial drop in human Chorionic gonadotropin levels in predicting a response to methotrexate in women with low-risk gestational trophoblastic neoplasia.
    Banach P; Zaborowski MP; Izycka N; Romala A; Nowak-Markwitz E
    Ginekol Pol; 2019; 90(3):141-147. PubMed ID: 30950003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The WHO score predicts treatment outcome in low risk gestational trophoblastic neoplasia patients treated with weekly intramuscular methotrexate.
    Gilani MM; Fariba B; Behtash N; Ghaemmaghami F; Moosavi AS; Rezayof E
    J Cancer Res Ther; 2013; 9(1):38-43. PubMed ID: 23575072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.